Benzinga's Top #PreMarket Losers

shares fell 32.08 percent to $0.72 in pre-market trading after the company reported that it will discontinue an ongoing Phase 3 study of CLBS20 as monotherapy for metastatic melanoma.

shares fell 21.58 percent to $9.05 in pre-market trading after the company priced 13.33 million share offering at $9.00 per share.

shares fell 16.22 percent to $15.50 in pre-market trading after the company reported downbeat Q3 results and issued a weak earnings forecast. The company also reported that Sam Sato will succeed Glenn Lyon as CEO.

fell 9.38 percent to $8.70 in pre-market trading after the company priced 7.25 million share offering at $9.00 per share.

shares fell 8.28 percent to $7.86 in pre-market trading following Wednesday Bloomberg report that

was reconsidering its $9.00 per share bid for Atmel.

shares fell 6.70 percent to $11.00 in pre-market trading after the company reported weaker-than-expected Q4 results.